Foundation Medicine, Inc. (NASDAQ:FMI) Files An 8-K Other Events

Foundation Medicine, Inc. (NASDAQ:FMI) Files An 8-K Other Events
Item 8.01. Other Events.

99.1 Press release issued by Foundation Medicine, Inc. dated November 30, 2017.
Story continues below

Foundation Medicine, Inc. Exhibit
EX-99.1 2 a51723629ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 FDA Approves Foundation Medicine’s FoundationOne CDx™,…
To view the full exhibit click here

About Foundation Medicine, Inc. (NASDAQ:FMI)

Foundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company’s segment is the business of delivering molecular information about cancer to its customers. Its products provide genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its flagship clinical molecular information products, FoundationOne for solid tumors, and FoundationOne Heme for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma and advanced sarcomas, are genomic profiles designed for use in the routine care of patients with cancer. Its other products include FoundationACT (Assay for Circulating Tumor deoxyribonucleic acid (DNA)), GeneKit, FoundationCORE, FoundationICE and the SmartTrials program.

An ad to help with our costs